Alpuente A, et al. - In treatment with OnabotulinumtoxinA, researchers analyzed the clinical features of long-term follow-up in patients with chronic and high-frequency episodic migraine. According to ICHD-3beta, patients diagnosed with high-frequency episodic migraine (HFEM) or chronic migraine (CM) were included. At each study time point, a comparative analysis was performed identifying outcome measures based on initial diagnosis and duration of treatment. According to results, 578 patients were selected and outcome data were gathered from 100 patients after 24 months (84.0% CM and 16.0% HFEM). Headache frequency was significantly lower by 10.5 days from baseline, 64.0% reported a ≥50% reduction in pain intensity and 70.0% of patients had ≥50% reduction in analgesic use at 24 months. The mean decrease in frequency was similar in CM and HFEM at 12 months, Findings revealed that the effectiveness of OnabotulinumtoxinA is significant in frequency and analgesic intake at 6 months and remains stable during follow-up